Sales and earnings on target at IS Pharma

NORTH West pharmaceutical group IS Pharma continues to hit management targets.

In a trading update ahead of interim results for the six months to September 30, the firm described trading as “strong” and said sales, gross profit and profit after tax in the period were in line with expectations.

The Chester-based company, which is listed on AIM, specialises in buying, developing and marketing hospital medicines.

“The board look forward to providing a detailed update when the interim results for the six months to September 30 are released, which is scheduled for November 10,” said the firm in a statement.

Earlier in the month IS Pharma declared it would pay its first dividend at the March year-end to reflect a strong and sustainable increase in revenues and profits.